Tango Therapeutics, Inc.
TNGX
Ранг среди акций
#4546
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Цена акции
$27.18
Последняя синхронизация: 2026-07-31
Рыночная капитализация
$3.38B
Изменение (1 день)
-1.41%
Изменение (1 год)
202.34%
Страна
US
Торговля Tango Therapeutics, Inc. (TNGX)
Категория
Healthcare
Коэффициент P/S для Tango Therapeutics, Inc. (TNGX)
Коэффициент P/S на October 2026 TTM: 67.14
Согласно последним финансовым отчетам и цене акций Tango Therapeutics, Inc., текущий коэффициент P/S (TTM) составляет 67.14. В конце 2023 он составлял 25.63.
История P/S для Tango Therapeutics, Inc. с 2019 по 2026
Коэффициент P/S в конце каждого года
| Год | P/S | Изменить |
|---|---|---|
| 2026 (TTM) | 67.14 | 737.15% |
| 2024 | 8.02 | -68.70% |
| 2023 | 25.63 | 0.08% |
| 2022 | 25.61 | 39.62% |
| 2021 | 18.34 | -61.56% |
| 2020 | 47.71 | 1,179.46% |
| 2019 | 3.73 | 0.00% |
Коэффициент P/S для аналогичных компаний или конкурентов
| Компания | P/S | Разница P/S | Страна |
|---|---|---|---|
| 10.02 | -85.07% |
US
|
|
| 40.55 | -39.60% |
US
|
|
| 3.96 | -94.10% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -84.89% |
NL
|
